Our TEAM

Founder and President of Epigenesis, a purpose-driven benefit corporation dedicated to stopping, slowing, and ultimately reversing dementia and other neurodegenerative diseases through holistic, science-informed treatment models. His leadership is rooted in a deep commitment to addressing the biological, environmental, and systemic factors that contribute to cognitive decline, while restoring dignity, function, and hope to patients and families. As President,

Barry provides mission-level vision and organizational stewardship, ensuring that Epigenesis remains firmly aligned with patient-centered outcomes, ethical innovation, and long-term impact. He works closely with executive leadership, researchers, clinicians, and strategic partners to guide the company’s direction, helping translate emerging research into practical, scalable solutions that can be responsibly delivered to those in need.

Barry also plays a central role in shaping and supporting the Telos Foundation, an affiliated nonprofit dedicated to advancing research, education, and access related to neurodegenerative disease. Through this dual structure, he helps align for-profit innovation with nonprofit purpose—ensuring that scientific advancement, public benefit, and financial sustainability reinforce one another rather than compete. Known for his thoughtful, values-driven leadership,

Barry brings clarity, balance, and integrity to complex challenges. His work reflects a long-term commitment to transforming how neurodegenerative diseases are understood, treated, and prevented—bridging compassion, research, and action to create lasting change.

As Chief Medical Officer, Steven will use clinical leadership and strategic oversight for the company’s mission to prevent, slow, and ultimately reverse neurodegenerative disease through evidence-based, integrative care models.

Dr. Cruikshank brings more than three decades of medical experience spanning conventional medicine, advanced surgical practice, and functional and integrative medicine. A graduate of Wake Forest University School of Medicine, he completed residency training at the University of Iowa and built a distinguished career in obstetrics and gynecology, including complex reconstructive and urogynecologic surgery.

His clinical foundation in traditional medicine provides a rigorous framework for safety, diagnostics, and outcomes-driven care. Following his surgical career, Dr. Cruikshank pursued advanced fellowship training in functional, regenerative, and integrative medicine, earning board-level credentials and becoming a recognized leader in personalized, root-cause-focused healthcare. His work emphasizes precision diagnostics, metabolic and inflammatory optimization, hormone and nutrient balance, and lifestyle-driven disease modification.

At Epigenesis, Dr. Cruikshank leads the development of clinical protocols, therapeutic standards, and interdisciplinary care models that integrate epigenetic science, advanced diagnostics, and patient-centered treatment pathways. His leadership ensures that Epigenesis’ scientific innovations translate into safe, ethical, and scalable clinical solutions that advance cognitive health and restore quality of life.

With decades of experience guiding complex organizations through growth, transformation, and scale, Dean brings a disciplined yet visionary approach to building systems that support Epigenesis’s mission to combat Alzheimer’s disease, dementia, and other neurodegenerative conditions.

Throughout his career, Dean has led large, distributed teams, overseen multimillion-dollar technology and infrastructure initiatives, and designed operational frameworks that translate research and innovation into real-world impact. His background spans cloud architecture, data strategy, cybersecurity, enterprise operations, and governance—expertise that enables Epigenesis to operate securely, efficiently, and with long-term scalability.

At Epigenesis, Dean is responsible for business strategy, cross-functional integration, risk management, and execution of the company’s clinical, research, and technology initiatives. He works closely with scientific, medical, and leadership teams to ensure that innovation is matched with strong operational foundations, ethical governance, and measurable outcomes. Dean’s leadership ensures that Epigenesis remains mission-driven, patient-focused, and prepared to deliver transformative solutions in neurodegenerative healthcare.

With more than 15 years of executive leadership across technology, sales, and operations, Patrick brings a disciplined, revenue-focused approach to advancing complex scientific innovation.

At Epigenesis, Patrick is responsible for aligning long-term business strategy with research and development objectives. He leads revenue architecture, strategic planning, and organizational design to ensure that breakthrough scientific work is supported by scalable, ethical, and sustainable funding models. His work focuses on building diversified revenue streams, strategic partnerships, and commercialization pathways that directly fuel research, accelerate development, and expand the company’s ability to deliver meaningful patient impact.

Patrick plays a key role in structuring research pipelines, translating complex scientific and technical initiatives into clear, executable strategies for investors, partners, and stakeholders. He works closely with researchers, clinicians, and advisors to align discovery, validation, and deployment into a cohesive, fundable roadmap. Previously, Patrick built and scaled technology-driven organizations across SaaS, systems integration, and managed services, consistently driving revenue growth, managing full P&L ownership, and leading high-performing teams. As Chief Strategic Officer, he applies this experience to help Epigenesis transform innovation into sustainable solutions that advance the fight against neurodegenerative disease.

Supporting the organization’s mission to advance innovative solutions for Alzheimer’s disease, dementia, and other neurodegenerative conditions. Currently completing graduate-level studies in finance and strategic management, he brings a strong analytical foundation combined with hands-on experience gained while helping build Epigenesis from its early stages.

Working closely with Barry Spiker and Patrick Hamilton, he has played an integral role in financial coordination, planning, and infrastructure development across both Epigenesis and its affiliated initiatives. His responsibilities include financial modeling, budget development, capital planning, compliance readiness, and the coordination of funding strategies that align scientific research with long-term sustainability. He has been actively involved in preparing the financial frameworks required for the launch of the Telos Foundation and the continued growth of Epigenesis Corporation, ensuring alignment between nonprofit and for-profit structures, mission integrity, and regulatory expectations.

With a focus on transparency, fiscal discipline, and mission-aligned growth, he supports leadership by translating complex financial data into actionable insight. As CFO, his role is centered on building resilient financial systems that enable Epigenesis to responsibly scale research, partnerships, and impact in the fight against neurodegenerative disease.